Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Haematologica|October 24, 2009
Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trialsMarleen A E van der Kaaij, Natacha Heutte, Jannie van Echten-Arends, et al.British Journal of Haematology|August 27, 2010
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95Audrey Simon, Michel Peoch, Philippe Casassus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trialsEvert M Noordijk, Patrice Carde, Noëlle Dupouy, et al.Cytometry. Part B, Clinical Cytometry|October 7, 2011
Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS studyFrançoise Durrieu, Franck Geneviève, Christine Arnoulet, et al.International Journal of Radiation Oncology, Biology, Physics|June 7, 2005
Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884)Berthe M P Aleman, Théodore Girinsky, Richard W M van der Maazen, et al.Blood|March 17, 2011
Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLCLaurent Sutton, Sylvie Chevret, Olivier Tournilhac, et al.Blood|September 22, 2005
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyThierry Facon, Jean-Yves Mary, Brigitte Pégourie, et al.European Journal of Cancer (Oxford, England : 1990)|June 12, 2017
ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trialChristophe Fermé, José Thomas, Pauline Brice, et al.International Journal of Radiation Oncology, Biology, Physics|December 13, 2017
Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized TrialJosé Thomas, Christophe Fermé, Evert M Noordijk, et al.The New England Journal of Medicine|June 13, 2003
Involved-field radiotherapy for advanced Hodgkin's lymphomaBerthe M P Aleman, John M M Raemaekers, Umberto Tirelli, et al.Pageof 3